Lung Cancer
Conference Coverage
The shifting sands of lung cancer screening
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
News
New KRAS inhibitor shows promise in NSCLC
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
Commentary
Drugging the undruggable
Targeted therapies are the ideal in drug development. New drugs that target KRAS (G12C) mutations mark a significant leap forward in oncology.
News
Quality of life benefit exaggerated in some cancer studies
News
Cancer may increase risk of type 2 diabetes
Study demonstrates elevated risk of developing diabetes for people with lung, pancreatic, breast, brain, urinary tract, or uterine cancers
News
Good chemo vs. bad chemo: When too much is a bad thing
Study questions the use of inpatient chemotherapy pointing to negative outcomes and high mortality among some patients.
Opinion
My picks for best of ASCO 2022
First-line treatment for colorectal cancer, possible new standard of care for breast cancer, and more.
Opinion
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
Phase 3 trials are needed to determine whether neoadjuvant chemo/immunotherapy outperforms adjuvant chemo/immunotherapy.
News
Evidence still lacking that vitamins prevent CVD, cancer: USPSTF
In its final recommendation statement on the subject, the task force does, however, recommend against use of vitamin E and beta-carotene.
Conference Coverage
Promising treatment option for incurable lung cancer described as ‘significant’
Investigators suggest this combo should be standard therapy for NSCLC going forward.
